Comparative study of misoprostol vs dinoprostone for induction of labour.
Various methods of induction of labour may be associated with risk and complications. Therefore, this study has been undertaken to compare the safety and efficacy of intra-vaginal misoprostol (PGE1 analogue) with intra-cervical dinoprostone (PGE2) in progress and induction of labour, the maternal side effects and the foetal outcome. 40 pregnant women aged between 16-35 years with indication of induction of labour participated in the study. Twenty patients (control) were administered 0.5 mg dinoprostone intra-cervically, 12 hourly while 20 patients (study group) were given misoprostol 100 microg, 4 hourly, intravaginally. The mean induction of labour initiation interval was 2.08 +/- 1.46 hours in study group and 2.21 +/- 1.20 hours in dinoprostone group. The Induction delivery interval was 6.92 +/- 4.01 hours in misoprostol group and 12.54 +/- 7.73 in dinoprostone group, whereas vaginal route of delivery was 95% in misoprostol group and 85% in dinoprostone group. Average dosages required were 1.55 +/- 1.02 in misoprostol group and 1.30 +/- 0.46 in dinoprostone group. All these result were statistically significant. Very few maternal side effects were reported in study group. There was no significant difference in foetal out come in either group. Therefore, it can be concluded that misoprostol is easy to administer and is cheap, effective, safe and convenient drug for induction of labour.
Kulshreshtha
S
S
Department of Pharmacology, S.N. Medical College and Associated Hospitals, Agra. drshobha@indiatimes.com
Sharma
P
P
Mohan
G
G
Singh
Sunita
S
Singh
Saroj
S
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D001034:Apgar Score; D002584:Cervix Uteri / Q000187:drug effects; D003967:Diarrhea / Q000139:chemically induced; D015232:Dinoprostone / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D005782:Gels; D006801:Humans; D007751:Labor, Induced / Q000379:methods*; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D009123:Muscle Hypotonia / Q000139:chemically induced; D010120:Oxytocics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D011247:Pregnancy; D011256:Pregnancy Outcome; D013607:Tablets; D013997:Time Factors; D014590:Uterine Contraction / Q000187:drug effects*; D014839:Vomiting / Q000139:chemically induced
D005782:Gels; D010120:Oxytocics; D013607:Tablets; D016595:Misoprostol; D015232:Dinoprostone